Advanced search
2 files | 18.26 MB Add to list

RIPK1 kinase-dependent inflammation and cell death contribute to the pathogenesis of COPD

Author
Organization
Project
Abstract
Rationale: Receptor-interacting protein kinase 1 (RIPK1) is a key mediator of regulated cell death (including apoptosis and necroptosis) and inflammation, both drivers of chronic obstructive pulmonary disease (COPD) pathogenesis. Objective: We aimed to define the contribution of RIPK1 kinase-dependent cell death and inflammation in the pathogenesis of COPD. Methods: We assessed RIPK1 expression in single-cell RNA-sequencing data from human and mouse lungs and validated RIPK1 levels in lung tissue of COPD patients via immunohistochemistry. Next, we assessed the consequences of genetic and pharmacological inhibition of RIPK1 kinase activity in experimental COPD, using Ripk1S25D /S25D kinase deficient mice and the RIPK1 kinase inhibitor GSK'547. Measurements and main results: RIPK1 expression increased in alveolar type I (AT1), AT2, ciliated and neuroendocrine cells in human COPD. RIPK1 protein levels were significantly increased in airway epithelium of COPD patients, compared to never smokers and smokers without airflow limitation. In mice, exposure to cigarette smoke (CS) increased Ripk1 expression similarly in AT2 cells, and further in alveolar macrophages and T cells. Genetic and/or pharmacological inhibition of RIPK1 kinase activity significantly attenuated airway inflammation upon acute and subacute CS-exposure, as well as airway remodeling, emphysema and apoptotic and necroptotic cell death upon chronic CS-exposure. Similarly, pharmacological RIPK1 kinase inhibition significantly attenuated elastase-induced emphysema and lung function decline. Finally, RNA-sequencing on lung tissue of CS-exposed mice revealed downregulation of cell death and inflammatory pathways upon pharmacological RIPK1 kinase inhibition. Conclusions: RIPK1 kinase inhibition is protective in experimental models of COPD and may represent a novel promising therapeutic approach.
Keywords
Pulmonary and Respiratory Medicine

Downloads

  • AAM VanEeckhoutte.pdf
    • full text (Accepted manuscript)
    • |
    • open access
    • |
    • PDF
    • |
    • 16.69 MB
  • (...).pdf
    • full text (Published version)
    • |
    • UGent only
    • |
    • PDF
    • |
    • 1.57 MB

Citation

Please use this url to cite or link to this publication:

MLA
Van Eeckhoutte, Hannelore, et al. “RIPK1 Kinase-Dependent Inflammation and Cell Death Contribute to the Pathogenesis of COPD.” EUROPEAN RESPIRATORY JOURNAL, vol. 61, no. 4, 2023, doi:10.1183/13993003.01506-2022.
APA
Van Eeckhoutte, H., Donovan, C., Kim, R. Y., Conlon, T. M., Ansari, M., Khan, H., … Bracke, K. (2023). RIPK1 kinase-dependent inflammation and cell death contribute to the pathogenesis of COPD. EUROPEAN RESPIRATORY JOURNAL, 61(4). https://doi.org/10.1183/13993003.01506-2022
Chicago author-date
Van Eeckhoutte, Hannelore, Chantal Donovan, Richard Y. Kim, Thomas M. Conlon, Meshal Ansari, Haroon Khan, Ranjith Jayaraman, et al. 2023. “RIPK1 Kinase-Dependent Inflammation and Cell Death Contribute to the Pathogenesis of COPD.” EUROPEAN RESPIRATORY JOURNAL 61 (4). https://doi.org/10.1183/13993003.01506-2022.
Chicago author-date (all authors)
Van Eeckhoutte, Hannelore, Chantal Donovan, Richard Y. Kim, Thomas M. Conlon, Meshal Ansari, Haroon Khan, Ranjith Jayaraman, Nicole G. Hansbro, Yves Dondelinger, Tom Delanghe, Allison M. Beal, Brad Geddes, John Bertin, Tom Vanden Berghe, Joyceline De Volder, Tania Maes, Peter Vandenabeele, Bart M. Vanaudenaerde, Dieter Deforce, Sonja Skevin, Filip Van Nieuwerburgh, Fien Verhamme, Guy Joos, Sobia Idrees, Herbert B. Schiller, Ali Önder Yildirim, Alen Faiz, Mathieu Bertrand, Guy Brusselle, Philip M. Hansbro, and Ken Bracke. 2023. “RIPK1 Kinase-Dependent Inflammation and Cell Death Contribute to the Pathogenesis of COPD.” EUROPEAN RESPIRATORY JOURNAL 61 (4). doi:10.1183/13993003.01506-2022.
Vancouver
1.
Van Eeckhoutte H, Donovan C, Kim RY, Conlon TM, Ansari M, Khan H, et al. RIPK1 kinase-dependent inflammation and cell death contribute to the pathogenesis of COPD. EUROPEAN RESPIRATORY JOURNAL. 2023;61(4).
IEEE
[1]
H. Van Eeckhoutte et al., “RIPK1 kinase-dependent inflammation and cell death contribute to the pathogenesis of COPD,” EUROPEAN RESPIRATORY JOURNAL, vol. 61, no. 4, 2023.
@article{01GWSCCK6GHJPR9S5TVXBN8XH4,
  abstract     = {{Rationale: Receptor-interacting protein kinase 1 (RIPK1) is a key mediator of regulated cell death (including apoptosis and necroptosis) and inflammation, both drivers of chronic obstructive pulmonary disease (COPD) pathogenesis.
Objective: We aimed to define the contribution of RIPK1 kinase-dependent cell death and inflammation in the pathogenesis of COPD.
Methods: We assessed RIPK1 expression in single-cell RNA-sequencing data from human and mouse lungs and validated RIPK1 levels in lung tissue of COPD patients via immunohistochemistry. Next, we assessed the consequences of genetic and pharmacological inhibition of RIPK1 kinase activity in experimental COPD, using Ripk1S25D /S25D kinase deficient mice and the RIPK1 kinase inhibitor GSK'547.
Measurements and main results: RIPK1 expression increased in alveolar type I (AT1), AT2, ciliated and neuroendocrine cells in human COPD. RIPK1 protein levels were significantly increased in airway epithelium of COPD patients, compared to never smokers and smokers without airflow limitation. In mice, exposure to cigarette smoke (CS) increased Ripk1 expression similarly in AT2 cells, and further in alveolar macrophages and T cells. Genetic and/or pharmacological inhibition of RIPK1 kinase activity significantly attenuated airway inflammation upon acute and subacute CS-exposure, as well as airway remodeling, emphysema and apoptotic and necroptotic cell death upon chronic CS-exposure. Similarly, pharmacological RIPK1 kinase inhibition significantly attenuated elastase-induced emphysema and lung function decline. Finally, RNA-sequencing on lung tissue of CS-exposed mice revealed downregulation of cell death and inflammatory pathways upon pharmacological RIPK1 kinase inhibition.
Conclusions: RIPK1 kinase inhibition is protective in experimental models of COPD and may represent a novel promising therapeutic approach.}},
  articleno    = {{2201506}},
  author       = {{Van Eeckhoutte, Hannelore and Donovan, Chantal and Kim, Richard Y. and Conlon, Thomas M. and Ansari, Meshal and Khan, Haroon and Jayaraman, Ranjith and Hansbro, Nicole G. and Dondelinger, Yves and Delanghe, Tom and Beal, Allison M. and Geddes, Brad and Bertin, John and Vanden Berghe, Tom and De Volder, Joyceline and Maes, Tania and Vandenabeele, Peter and Vanaudenaerde, Bart M. and Deforce, Dieter and Skevin, Sonja and Van Nieuwerburgh, Filip and Verhamme, Fien and Joos, Guy and Idrees, Sobia and Schiller, Herbert B. and Yildirim, Ali Önder and Faiz, Alen and Bertrand, Mathieu and Brusselle, Guy and Hansbro, Philip M. and Bracke, Ken}},
  issn         = {{0903-1936}},
  journal      = {{EUROPEAN RESPIRATORY JOURNAL}},
  keywords     = {{Pulmonary and Respiratory Medicine}},
  language     = {{eng}},
  number       = {{4}},
  pages        = {{18}},
  title        = {{RIPK1 kinase-dependent inflammation and cell death contribute to the pathogenesis of COPD}},
  url          = {{http://doi.org/10.1183/13993003.01506-2022}},
  volume       = {{61}},
  year         = {{2023}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: